The Alpha-Fetoprotein (AFP) and AFP-L3 Test measures total AFP and the AFP-L3 fraction, which is more specific for liver cancer risk. Elevated AFP may indicate liver disease, germ cell tumors, or hepatitis, while AFP-L3 is strongly associated with hepatocellular carcinoma (HCC). Doctors order this test to assess liver function, screen high-risk patients, and monitor cancer treatment. Results provide critical insight into liver health and cancer detection.

The Alpha Fetoprotein (AFP) Tumor Marker Test measures AFP levels in blood to help detect and monitor cancers such as liver cancer, testicular cancer, and certain ovarian tumors. Elevated AFP may also be seen with liver disease, cirrhosis, or hepatitis. Doctors order this test for patients at risk of or being treated for cancer. Results provide essential insight for diagnosis, monitoring treatment response, and tracking cancer recurrence or progression.

The Maternal AFP Test evaluates alpha-fetoprotein levels during pregnancy to assess fetal development and identify possible abnormalities. Variations in AFP may signal neural tube defects, abdominal wall issues, or genetic conditions such as trisomy 21. As part of prenatal screening, this test provides insight into maternal health and supports early evaluation of fetal growth and pregnancy outcomes.

 The Cancer Screening - Men panel is a comprehensive diagnostic tool designed to detect early signs of various cancers in men. This panel includes a series of tests that measure specific biomarkers associated with different types of cancer. By assessing these biomarkers, healthcare providers can identify the presence of cancer at an early stage, when treatment is often more effective. This panel is crucial for men who are at higher risk of developing cancer due to factors such as age, family history, or lifestyle.

The Cancer Screening - Women Panel is a comprehensive set of blood tests designed to detect various cancer markers in women. This panel assesses levels of specific proteins that can be elevated in the presence of certain types of cancer. By measuring these markers, healthcare providers can gain valuable insights into a patient's risk of having cancer, monitor the progression of the disease, and evaluate the effectiveness of treatment.

 The CA-1 Cancer Screening - Women panel is specifically designed as an initial screening tool for the early detection of various cancers that commonly affect women. This panel combines several tumor markers and protein measurements, each carefully selected for their relevance in detecting specific cancer types. The panel is an important resource for those who are at increased risk of cancer, either due to family history, genetic predisposition, or other risk factors. By measuring specific biomarkers, this panel helps in identifying cancer at an early stage, where treatment can be more effective and less invasive.

The LH-2 Liver Health panel is a comprehensive suite of tests designed to evaluate liver function, identify liver damage, and screen for specific liver disorders. This panel includes Quantitative Alpha-1-Antitrypsin, Alpha-Fetoprotein and AFP-L3, Fractionated Bilirubin (Direct, Indirect, and Total), Ceruloplasmin, Comprehensive Metabolic Panel, Gamma Glutamyl Transferase, Iron and Total Iron Binding Capacity, Lactate Dehydrogenase, and Prothrombin Time with INR. Each of these tests offers valuable insights into liver health, potential liver disease, and the liver's capacity to perform its vital functions.

 The CA-2 Cancer Screening - Women panel is a specialized diagnostic tool designed for the early detection and ongoing monitoring of various cancers specifically in women. It expands upon basic cancer screening by including additional markers that provide a wider range of detection and insight into different types of cancers. This panel is particularly valuable for women who are at increased risk due to genetic predispositions, family history, or environmental factors. It helps in the early identification of cancer, potentially improving the effectiveness of treatments and increasing the chances of successful outcomes.

 The CA-3 Cancer Screening - Women panel is an extensive diagnostic tool designed for an in-depth analysis of various cancer-related markers, specifically tailored for women. This advanced screening panel integrates additional markers to enhance the detection and monitoring capabilities for a broad spectrum of cancers. It is instrumental in providing a comprehensive overview of a woman's cancer risk profile, facilitating early intervention, and guiding effective treatment strategies.

 The CA-4 Cancer Screening - Women panel is the most comprehensive diagnostic tool available for assessing cancer risk and monitoring the health of women potentially at high risk for various cancers. It encompasses an extensive range of biomarkers, each specifically chosen to detect early signs of cancer and monitor treatment progress or recurrence. This panel is essential for women with a significant family history of cancer, known genetic predispositions, or those who have had previous cancer diagnoses and need close surveillance.

The LH-3 Liver Health panel is an extensive diagnostic tool designed to provide a comprehensive assessment of liver health. This panel includes a wide range of tests that evaluate liver function, screen for liver infections, and assess liver damage. It comprises Quantitative Alpha-1-Antitrypsin, Alpha-Fetoprotein and AFP-L3, Fractionated Bilirubin, Ceruloplasmin, Comprehensive Metabolic Panel, Copper, Gamma Glutamyl Transferase, Hepatitis A, B, and C antibodies and antigens, Iron and Total Iron Binding Capacity, Lactate Dehydrogenase, and Prothrombin Time with INR.

The LH-4 Liver Health panel is the most comprehensive suite of tests tailored to provide an in-depth evaluation of liver health, function, and the presence of liver diseases, including liver cancer and viral hepatitis. It encompasses a broad spectrum of markers, from liver enzymes and proteins to specific tests for genetic conditions, liver cancer markers, and comprehensive screening for hepatitis infections.